Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918 Authors: Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Abstract BACKGROUND: LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo. The effect of glucagon-like peptide-1 receptor agonist liraglutide on cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease is unknown. Liraglutide's treatment effects in patients with and without kidney disease were analyzed post hoc. METHODS: Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care. These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR;
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research

Related Links:

Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Ischemic stroke patients with T2DM and CKD were selected from the Taiwan National Health Insurance Research Database (NHIRD) from March 1, 2009 to December 31, 2011. A total of 1375 patients were divided into 2 age- and gender-matched groups: patients who received sitagliptin (n = 275; 20%) and those who did not (n = 1,100). Primary major adverse cardiac and cerebrovascular events (M...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Authors: Madievsky R Abstract Type 2 diabetes mellitus often goes hand in hand with cardiovascular and renal comorbidities. Stroke, myocardial infarction, heart failure, and chronic kidney disease are high-risk complications of type 2 diabetes that contribute to morbidity and mortality. Recent clinical trials have uncovered evidence that certain antidiabetic agents may confer cardiovascular and/or renal benefits such as reduced cardiovascular and all-cause mortality and reduced need for renal replacement therapy. Two landmark trials in particular, EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortal...
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
Abstract Although guidelines recommend strict blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, the long‐term effects of this approach are unknown. We investigated the effect of intensive BP control on clinical outcomes in patients with T2DM over 9 years of follow‐up. We included ACCORD BP participants in the standard glucose control arm who had established cardiovascular disease, chronic kidney disease, age ≥75 years or 10‐year coronary heart risk ≥15%. Participants were randomized to either intensive (systolic BP
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: BRIEF REPORT Source Type: research
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR]
Source: Journal of Diabetes - Category: Endocrinology Authors: Tags: Editorial Source Type: research
Persons with type 2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrat...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tags: Review Source Type: research
The objective of this study was to examine the benefits of using CAVI as a predictor of cardiovascular events in high-risk patients.Methods and Design: This prospective multicenter study to evaluate the usefulness of the CAVI to predict cardiovascular events in Japan (CAVI-J) is a cohort study with central registration. Participants (n = 3,000) will be scheduled to enroll and data will be collected for up to 5 years from entry of participants into the study. To be eligible to participate in the CAVI-J study, individuals have to be aged between 40 and 74 years and have at least one of the following risk factors for arterios...
Source: Pulse - Category: Cardiology Source Type: research
In conclusion, we showed for the first time that 7-KC induces oxidative stress via lysosomal dysfunction, resulting in exacerbation of calcification. CHIMERIC ANTIGEN RECEPTOR CANCER THERAPIES CAN NOW TARGET SOLID TUMORS https://www.fightaging.org/archives/2016/06/chimeric-antigen-receptor-cancer-therapies-can-now-target-solid-tumors/ If the research community is to win in the fight to cure cancer, and win soon enough to matter for all of us, then the focus must be on technology platforms that can be easily and cheaply adapted to many different types of cancer. The biggest strategic problem in the field is tha...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Stroke | Urology & Nephrology | Victoza